drugset
drugset / Press release

JANSSEN PRESENTS LONG TERM PHASE 3 EFFICACY AND SAFETY DATA OF SIRUKUMAB IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE AND/OR WHO WERE INTOLERANT TO ANTI-TNFs

2017-06-14 · Janssen Research & Development, LLC · original jnj.com ↗

Ad26.COV2.S Sirukumab · results

NEWS RELEASE JANSSEN PRESENTS LONG TERM PHASE 3 EFFICACY AND SAFETY DATA OF SIRUKUMAB IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE AND/OR WHO WERE INTOLERANT TO ANTI-TNFs 6/14/2017 1

The release as fetched from its publisher. jnj.com ↗